Showing results (61-70 of 172) with videos related to
Sort By:
Pageof 18
The Journal of Rheumatology|July 5, 2011
Developing disease activity and response criteria in connective tissue disease-related interstitial lung diseaseLesley Ann Saketkoo, Eric L Matteson, Kevin K Brown, et al.The Journal of Rheumatology|September 1, 1992
Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosisF M Wigley, J R Seibold, R A Wise, et al.Chest|June 8, 2013
Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern eraMelvyn Rubenfire, Mark D Huffman, Sangeetha Krishnan, et al.Journal of Clinical Pharmacology|October 12, 1999
Trimethoprim/sulfamethoxazole does not affect the steady-state disposition of indinavirM G Sturgill, J R Seibold, S E Boruchoff, et al.Pharmaceutical Research|June 1, 1994
Pharmacokinetics and bioinversion of ibuprofen enantiomers in humansH Cheng, J D Rogers, J L Demetriades, et al.Autoimmunity Reviews|October 31, 2021
Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidenceMadelon C Vonk, Vanessa Smith, Petros P Sfikakis, et al.Current Rheumatology Reviews|August 3, 2010
Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study DesignDinesh Khanna, James R Seibold, Athol Wells, et al.The Journal of Rheumatology|September 17, 2010
Discordance between patient and physician assessments of disease severity in systemic sclerosisMarie Hudson, Ann Impens, Murray Baron, et al.Annals of the Rheumatic Diseases|March 1, 1994
Anti-laminin autoantibodies in collagen vascular diseases: the use of adequate controls in studies of autoimmune responses to lamininD E Cohen, L D Kaufman, A A Varma, et al.Journal of Clinical Pharmacology|April 29, 1998
A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjectsD E Salazar, D R Much, P S Nichola, et al.Pageof 18